



THOMSON MEDICAL GROUP LIMITED

(Incorporated in the Republic of Singapore)
(Company Registration No. 199908381D)

UPDATE ON THE STATUS OF THE RESTORATION OF PUBLIC FLOAT - FURTHER EXTENSION OF TIME TO RESTORE THE PUBLIC FLOAT

1. INTRODUCTION

The Board of Directors (the “**Board**”) of Thomson Medical Group Limited (the “**Company**”) refers to the following announcements:

- (a) the announcement dated 12 September 2023 in relation to the loss of public float of the Company;
- (b) the announcement dated 19 September 2023 in relation to the Singapore Exchange Securities Trading Limited’s (the “**SGX-ST**”) confirmation that it has no objection to granting the Company a period of 3 months until 10 December 2023 for the public float to be restored and to not suspend trading in the Company’s shares on the SGX-ST in the meantime;
- (c) the announcement dated 7 December 2023 in relation to the SGX-ST granting the Company a further 1-month period till 10 January 2024 to explore options to restore the public float as required under Rule 723 of Listing Manual issued by the SGX-ST (the “**Listing Manual**”) and the continued trading of the Company’s shares during this period; and
- (d) the announcement dated 10 January 2024 (the “**10 January 2024 Announcement**”) in relation to the SGX-ST’s letter received by the Company on the same date rejecting the Company’s application for a further extension of time to restore the public float.

2. GRANT OF FURTHER EXTENSION OF TIME

Subsequent to the 10 January 2024 Announcement, the Company had on 12 January 2024 made an appeal to the SGX-ST for a re-consideration of its decision and for a further extension of time of 3 months until 10 April 2024 to restore its public float (the “**Further Extension**”) and to not suspend trading in the Company’s shares on the SGX-ST in the meantime.

The Company wishes to update the shareholders of the Company (“**Shareholders**”) that, following the Company’s appeal, the SGX-ST had on 17 January 2024 via a letter to Company informed that based on the submissions and representations provided, the SGX-ST has no objection to:

- (a) granting the Company a further period of 3 months until 10 April 2024 to explore options to restore its public float as required under Rule 723 of the Listing Manual; and
- (b) the continued trading of the Company's shares during this period.

The Further Extension is subject to the Company monitoring the public float and trading activity in its shares on an ongoing basis, and making an immediate request for a trading halt if there is any indication of disorderly trading.

3. CAUTION IN TRADING

The Company will make such announcements as may be necessary and/or appropriate to update Shareholders on the restoration of its public float, including but not limited to the completion of the restoration of its public float and/or request for a trading halt in the event of any indication of disorderly trading.

In the meantime, trading of the Company's shares on the Mainboard of the SGX-ST will continue. Shareholders and investors are advised to exercise caution when dealing in the securities of the Company. Shareholders and investors should consult their stockbrokers, bank managers, solicitors or other professional advisers if they have any doubt about the actions they should take.

By Order of the Board
THOMSON MEDICAL GROUP LIMITED

Dr Heng Jun Li Melvin
Executive Director and Group CEO
17 January 2024